New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
10:02 EDTSGEN, UMPQ, SLB, SIG, RDS.A, CRR, AXP, RTOKY, ITW, E, BRCM, ACMP, MATX, HFC, DB, AINV, KKR, GOLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Access Midstream (ACMP) upgraded to Buy from Neutral at Ladenburg... American Express (AXP) upgraded at Guggenheim... Apollo Investment (AINV) upgraded to Buy from Neutral at SunTrust... Broadcom (BRCM) upgraded to Outperform from Perform at Oppenheimer... CARBO Ceramics (CRR) upgraded to Neutral from Sell at Guggenheim... Deutsche Bank (DB) upgraded to Overweight from Neutral at JPMorgan... Eni SpA (E) upgraded to Buy from Hold at Deutsche Bank... GOL Linhas (GOL) upgraded to Outperform from Market Perform at Raymond James... HollyFrontier (HFC) upgraded to Outperform at Wells Fargo... Illinois Tool Works (ITW) upgraded to Buy from Hold at Argus... KKR (KKR) upgraded to Outperform from Neutral at Credit Suisse... Matson (MATX) upgraded to Buy from Hold at BB&T... Rentokil (RTOKY) upgraded to Outperform from Neutral at Credit Suisse... Royal Dutch Shell (RDS.A) upgraded to Buy from Hold at Deutsche Bank... Schlumberger (SLB) upgraded to Overweight from Neutral at HSBC... Seattle Genetics (SGEN) upgraded to Buy from Neutral at UBS... Signet Jewelers (SIG) resumed with an Overweight from Neutral at JPMorgan... Umpqua Holdings (UMPQ) upgraded to Equal Weight from Underweight at Barclays.
News For A;SLB;SGEN;SIG;UMPQ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
10:01 EDTSIGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:04 EDTSGENSeattle Genetics initiates Phase 1/2 trial of ADCETRIS
Seattle Genetics (SGEN) announced that it has initiated a phase 1/2 clinical trial of ADCETRIS in combination with Opdivo for patients with relapsed or refractory Hodgkin lymphoma, or HL, after failure of frontline treatment. The trial is being conducted under a previously announced clinical trial collaboration agreement with Bristol-Myers Squibb (BMY). ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL, which combines the targeting ability of a monoclonal antibody with a highly potent cell-killing agent. Opdivo is a human antibody that targets and inhibits the programmed death receptor-1, resulting in T-cell activation. Opdivo is part of a new class of cancer immunotherapy treatments known as checkpoint inhibitors, which are designed to harness the body's own immune system in fighting cancer by targeting distinct regulatory components of the immune system. A second trial under the collaboration is planned to begin later in 2015 for relapsed or refractory B-cell and T-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma.
07:33 EDTSIGSignet Jewelers initiated with a Buy at Citi
Target $170.
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.
06:42 EDTSIGMerrill Lynch to face class action over Zale sale, Reuters reports
Subscribe for More Information
September 30, 2015
15:02 EDTSLBSchlumberger won't buy stake in Russia's Eurasia Drilling, WSJ says
Schlumberger's $1.7B deal for a stake Russia's onshore drilling firm Eurasia Drilling has been called off after Russian authorities failed to approve the deal by Schlumberger's deadline, says the Wall Street Journal. Reference Link
07:59 EDTSLBSchlumberger estimates lowered by about 20% for 2016, 2017 at UBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use